• The Committee is responsible for maintaining the Lothian Joint Formulary (launched May 2001) which recommends first and second choice drugs, dosages and key points of information.
  • The Committee considers proposed changes, additions and deletions to the Formulary from clinicians, pharmacists and nurses via the Lothian Formulary Pharmacist.
  • The Committee advises and collaborates with the Drugs and Therapeutics Committee on issues of presentation, format and implementation of the Formulary.
  • The Committee advises on SMC and NICE/SIGN/NHS QIS recommendations on new drugs.
  • The Commmittee reviews and advises on MHRA safety advice.

The constitution provides full details of committee business.